Stock listing
TASE:BLRX BioLineRX Ltd. מניה
Home listing (TASE) of BioLineRX Ltd.
Follow BioLineRX Ltd. into a list and get an email when it puts out news.
Share price · TASE:BLRX
1.00 ILA (agorot) 0.00 (0.0%)
Close on Nov 19, 2026
- Day range
- 1.00 – 1.00 ILA (agorot)Nov 19, 2026
- Volume
- 700,000 sharesNov 19, 2026
- Market cap
- 29.87M ILSAt the close on Nov 19, 2026 · price × 2.99B shares outstanding
- 52-week range
- 1.00 – 2.00 ILA (agorot)Lowest and highest trades, Nov 20, 2025 – Nov 19, 2026
- Traded on an average day
- 42,259 ILSMedian day 2.34M shares · 2 days with no trades · last 3 months, Aug 19, 2026 – Nov 19, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TASE:BLRX · Home | 1.00 ILA (agorot) | 0.00 (0.0%) | 700,000 | 1.00 | 1.00 | 1.00 | 1.00 | Close on Nov 19, 2026 |
| NASDAQ:BLRX | $0.964 USD | -0.096 (-9.1%) | 38,775 | $1.096 | $1.096 | $0.780 | $1.060 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 19, 2026 – Nov 19, 2026 · TASE:BLRX · ILA (agorot), adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 700,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 900,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 600,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 200,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 400,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 700,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 200,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 50,000 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.00 | 1.00 | 0 | |
| 1.00 | -0.10 | -9.1% | 1.00 | 1.10 | 1.00 | 1,625,200 | |
| 1.10 | +0.10 | +10.0% | 1.00 | 1.10 | 1.00 | 6,753,917 | |
| 1.00 | 0.00 | 0.0% | 1.00 | 1.10 | 1.00 | 1,383,000 | |
| 1.00 | -0.10 | -9.1% | 1.00 | 1.10 | 1.00 | 4,785,451 | |
| 1.10 | 0.00 | 0.0% | 1.10 | 1.10 | 1.00 | 782,873 | |
| 1.10 | 0.00 | 0.0% | 1.10 | 1.10 | 1.10 | 100,000 | |
| 1.10 | +0.10 | +10.0% | 1.00 | 1.10 | 1.00 | 1,348,066 | |
| 1.00 | -0.20 | -16.7% | 1.10 | 1.20 | 1.00 | 11,020,588 | |
| 1.20 | +0.10 | +9.1% | 1.10 | 1.20 | 1.10 | 1,457,394 | |
| 1.10 | -0.10 | -8.3% | 1.20 | 1.20 | 1.10 | 593,428 | |
| 1.20 | +0.10 | +9.1% | 1.10 | 1.20 | 1.10 | 103,454 | |
| 1.10 | 0.00 | 0.0% | 1.10 | 1.20 | 1.10 | 3,630,646 | |
| 1.10 | -0.10 | -8.3% | 1.20 | 1.20 | 1.00 | 9,649,668 | |
| 1.20 | +0.10 | +9.1% | 1.20 | 1.20 | 1.20 | 2,431,817 | |
| 1.10 | -0.10 | -8.3% | 1.10 | 1.20 | 1.10 | 7,257,431 | |
| 1.20 | 0.00 | 0.0% | 1.20 | 1.30 | 1.10 | 6,635,983 | |
| 1.20 | 0.00 | 0.0% | 1.20 | 1.30 | 1.20 | 5,015,601 | |
| 1.20 | 0.00 | 0.0% | 1.20 | 1.30 | 1.20 | 9,981,993 | |
| 1.20 | 0.00 | 0.0% | 1.20 | 1.30 | 1.20 | 2,645,741 | |
| 1.20 | 0.00 | 0.0% | 1.20 | 1.30 | 1.20 | 4,154,400 | |
| 1.20 | 0.00 | 0.0% | 1.20 | 1.30 | 1.20 | 911,840 | |
| 1.20 | 0.00 | 0.0% | 1.30 | 1.30 | 1.20 | 3,583,282 | |
| 1.20 | -0.10 | -7.7% | 1.30 | 1.30 | 1.20 | 2,863,589 | |
| 1.30 | -0.10 | -7.1% | 1.30 | 1.40 | 1.20 | 8,709,923 | |
| 1.40 | 0.00 | 0.0% | 1.30 | 1.40 | 1.30 | 714,283 | |
| 1.40 | +0.10 | +7.7% | 1.30 | 1.40 | 1.30 | 373,403 | |
| 1.30 | 0.00 | 0.0% | 1.30 | 1.40 | 1.30 | 1,425,362 | |
| 1.30 | +0.10 | +8.3% | 1.40 | 1.40 | 1.30 | 1,285,100 | |
| 1.20 | -0.10 | -7.7% | 1.30 | 1.40 | 1.20 | 3,185,320 | |
| 1.30 | 0.00 | 0.0% | 1.30 | 1.40 | 1.30 | 1,297,651 | |
| 1.30 | 0.00 | 0.0% | 1.30 | 1.40 | 1.30 | 3,025,847 | |
| 1.30 | 0.00 | 0.0% | 1.40 | 1.40 | 1.30 | 3,441,553 | |
| 1.30 | 0.00 | 0.0% | 1.30 | 1.40 | 1.30 | 14,754,104 | |
| 1.30 | 0.00 | 0.0% | 1.40 | 1.40 | 1.30 | 4,248,734 | |
| 1.30 | 0.00 | 0.0% | 1.30 | 1.40 | 1.30 | 5,113,703 | |
| 1.30 | -0.20 | -13.3% | 1.40 | 1.40 | 1.30 | 3,957,678 | |
| 1.50 | 0.00 | 0.0% | 1.50 | 1.50 | 1.30 | 5,034,182 | |
| 1.50 | +0.10 | +7.1% | 1.40 | 1.50 | 1.40 | 57,112 | |
| 1.40 | +0.10 | +7.7% | 1.40 | 1.50 | 1.40 | 395,656 | |
| 1.30 | -0.10 | -7.1% | 1.40 | 1.50 | 1.30 | 2,343,878 | |
| 1.40 | 0.00 | 0.0% | 1.40 | 1.50 | 1.30 | 3,995,603 | |
| 1.40 | -0.10 | -6.7% | 1.40 | 1.50 | 1.40 | 5,971,703 | |
| 1.50 | +0.10 | +7.1% | 1.40 | 1.50 | 1.40 | 20,148,276 | |
| 1.40 | -0.10 | -6.7% | 1.50 | 1.50 | 1.40 | 539,856 | |
| 1.50 | +0.10 | +7.1% | 1.50 | 1.50 | 1.50 | 375,762 | |
| 1.40 | -0.10 | -6.7% | 1.50 | 1.60 | 1.40 | 2,669,881 | |
| 1.50 | 0.00 | 0.0% | 1.60 | 1.60 | 1.40 | 3,611,319 | |
| 1.50 | -0.10 | -6.3% | 1.60 | 1.60 | 1.50 | 4,398,958 | |
| 1.60 | +0.10 | +6.7% | 1.60 | 1.60 | 1.60 | 526,968 | |
| 1.50 | 0.00 | 0.0% | 1.50 | 1.60 | 1.50 | 1,389,466 | |
| 1.50 | +0.10 | +7.1% | 1.50 | 1.60 | 1.50 | 8,099,666 |
Splits
1 split · TASE:BLRX · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-10 | Consolidation |
- Ticker
- TASE:BLRX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- TASE
- Currency
- ILA
What changed lately
Latest news release · Sep 10, 2026
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
Latest earnings call · Aug 31, 2026
BioLineRX (TASE:BLRX) Q2 2026 Earnings Call
Replay and transcript
Latest deck · July 2026
Investor Presentation (July 2026)
Investor deck · 39 slides
Latest news
BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026)
Sep 10, 2026
Closed 1.30 (0.0%) on Sep 10, 2026
BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update
May 27, 2026
Closed 1.50 (+7.1%) on May 27, 2026
BioLineRx to Report First Quarter 2026 Results on May 27, 2026
May 20, 2026
Closed 1.30 (-7.1%) on May 20, 2026
BioLineRx and Hemispherian Announce First Patient Dosed in Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Apr 28, 2026
Closed 1.20 (0.0%) on Apr 28, 2026
Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma
Apr 8, 2026
Closed 1.30 (0.0%) on Apr 9, 2026
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
Mar 26, 2026
Closed 1.30 (0.0%) on Mar 26, 2026
BioLineRx Reports 2025 Financial Results and Provides Corporate Update
Mar 23, 2026
Closed 1.30 (-7.1%) on Mar 23, 2026
BioLineRx to Report 2025 Annual Results on March 23, 2026
Mar 16, 2026
Closed 1.40 (-6.7%) on Mar 16, 2026
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 24, 2025
Closed 1.90 (+5.6%) on Nov 24, 2025
BioLineRX Ltd. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 9 in the last 12 months · 19 in all · newest Sep 10, 2026 · oldest 2025
- Calls
- 25 calls with a replay · 25 with a transcript · latest Aug 31, 2026
- Decks
- 37 decks · latest July 2026
Where BioLineRX Ltd. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TASE:BLRX · Home listing · This page | TASE | Israel | ILA |
| NASDAQ:BLRX | NASDAQ | United States | USD |
| BOATS:BLRX | BOATS | United States | USD |
| Frankfurt:YP2 | Frankfurt | Germany | EUR |
| gettex:YP2 | gettex | Germany | EUR |
| Lang & Schwarz:A41038 | Lang & Schwarz | Germany | EUR |
| Munich:YP2 | Munich | Germany | EUR |
| Stuttgart:YP2 | Stuttgart | Germany | EUR |
Valuation
EV/sales 8.6× against a median of 8.5×: 3rd lowest of 5 Biotechnology companies shown. Statements: Year to Dec 31, 2025 · price Nov 19, 2026
- Enterprise value
- 33.99M ILS
- P/E
- Loss
- EV/sales
- 8.6×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 0.5×
- Gross margin
- 80.5%
- Operating margin
- −871.8%
- Net margin
- −171.7%
- Debt to equity
- 0.3×
- Beta
- No index for this market yet
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| BioLineRX Ltd. · TASE:BLRX | US$8.90M | US$10.13M | n/a | 8.6× | n/a | 0.5× | −171.7% | 0.3× | n/a |
| Genvor Incorporated · OTC:GNVR | US$9.47M | US$9.27M | n/a | n/a | n/a | n/a | n/a | n/a | 0.44 |
| Poxel SA · EURONEXT:POXEL | US$9.27M | US$73.95M | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| TScan Therapeutics, Inc. · NASDAQ:TCRX | US$9.27M | −US$30.80M | n/a | −5.9× | n/a | 0.2× | n/a | 0.9× | 1.66 |
| Rapid Dose Therapeutics Corp · CSE:DOSE | US$9.13M | US$9.12M | n/a | 5.1× | n/a | n/a | −123.1% | n/a | 0.64 |
| CytoMed Therapeutics Limited · NASDAQ:GDTC | US$9.01M | US$8.23M | n/a | 14.7× | n/a | 2.3× | −730.3% | 0.1× | 0.16 |
| PreveCeutical Medical Inc · CSE:PREV | US$8.97M | US$8.95M | n/a | n/a | n/a | n/a | n/a | n/a | 0.73 |
| CalciMedica, Inc. · NASDAQ:CALC | US$8.69M | US$1.82M | n/a | n/a | n/a | 2.1× | n/a | 1.6× | 0.54 |
| Active Biotech AB · OMXSTO:ACTI | US$8.67M | US$4.38M | n/a | n/a | n/a | 2.4× | n/a | 0.0× | n/a |
| BioVie Inc. · NASDAQ:BIVI | US$8.58M | US$1.10M | n/a | n/a | n/a | 1.3× | n/a | 0.0× | 1.84 |
| Vyome Holdings, Inc. · NASDAQ:HIND | US$8.42M | US$1.82M | n/a | 11.9× | n/a | 1.3× | n/a | 0.1× | 1.34 |
| Median of the others | US$8.99M | US$6.31M | 8.5× | 1.7× | −426.7% | 0.1× | 0.69 |
Forecasts
Analysts' consensus from EODHD, read Nov 10, 2026. Not 6ix's view and not investment advice.
- Price target
- 954.07 ILA · Analysts' mean
- EPS, year to Dec 2026
- 0.00 · 1 analyst
- Revenue, year to Dec 2026
- 1.62M · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Philip A. Serlin | CHIEF EXECUTIVE OFFICER |
| Mali Zeevi | CHIEF FINANCIAL OFFICER |
| Bela Neiman | VICE PRESIDENT, ANALYTICAL CHEMISTRY |
| Efrat Halbfinger | VICE PRESIDENT, CHEMISTRY AND FORMULATION |
| Irit Gliko-Kabir | VICE PRESIDENT, CLINICAL OPERATIONS |
| Jael Birenberg | VICE PRESIDENT, REGULATORY AFFAIRS, QUALITY ASSURANCE & PHARMACOVIGILANCE |
| Ella Sorani | CHIEF DEVELOPMENT OFFICER |
Board
| Director | Role |
|---|---|
| Aharon Schwartz | CHAIRMAN |
| Avraham Molcho | BOARD MEMBER |
| BJ Bormann | BOARD MEMBER |
| Gal Cohen | BOARD MEMBER |
| Rafael Hofstein | BOARD MEMBER |
| Rami Dar | BOARD MEMBER |
| Sandra Panem | BOARD MEMBER |
| Shaoyu Yan | BOARD MEMBER |
Events
- Next results
- Nov 23, 2026
Calls
| Call | When | Status |
|---|---|---|
| BioLineRX (TASE:BLRX) Q3 2026 Earnings Call | Mon, Nov 23, 2026 · 8:30 AM ET | Upcoming |
| BioLineRX (TASE:BLRX) Q2 2026 Earnings Call | Mon, Aug 31, 2026 · 8:30 AM ET | Replay |
| BioLineRX (TASE:BLRX) Q1 2026 Earnings Call | Wed, May 27, 2026 · 8:30 AM ET | Replay |
| BioLineRX (TASE:BLRX) Q4 2025 Earnings Call | Mon, Mar 23, 2026 · 8:30 AM ET | Replay |
| BioLineRX (TASE:BLRX) Q3 2025 Earnings Call | Mon, Nov 24, 2025 · 8:30 AM ET | Replay |
| BioLineRX (TASE:BLRX) Q2 2025 Earnings Call | Thu, Aug 14, 2025 · 8:30 AM ET | Replay |
| BioLineRX (TASE:BLRX) Q1 2025 Earnings Call | Tue, May 27, 2025 · 8:30 AM ET | Replay |
| BioLineRX (TASE:BLRX) Q4 2024 Earnings Call | Mon, Mar 31, 2025 · 8:30 AM ET | Replay |
| BioLineRX (TASE:BLRX) Q3 2024 Earnings Call | Mon, Nov 25, 2024 · 8:30 AM ET | Replay |
| BioLineRX (TASE:BLRX) Q2 2024 Earnings Call | Thu, Aug 15, 2024 · 8:30 AM ET | Replay |
All 26 calls
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Jun 30, 2026 | Aug 31, 2026 · Before open | +7.1% |
| Quarter to Dec 31, 2025 | Mar 23, 2026 · Before open | −7.1% |
| Quarter to Sep 30, 2025 | Nov 24, 2025 · Before open | +5.6% |
| Q2 2025 | Aug 14, 2025 · Before open | 0.0% |
| Quarter to Dec 31, 2024 | Mar 31, 2025 · Before open | 0.0% |
| Quarter to Sep 30, 2024 | Nov 25, 2024 · Before open | −9.3% |
| Quarter to Dec 31, 2023 | Mar 26, 2024 · Before open | −11.4% |
| Quarter to Sep 30, 2023 | Nov 20, 2023 · Before open | −0.3% |
| Q2 2023 | Aug 30, 2023 · Before open | +2.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2026) | Investor deck | 39 slides | July 2026 |
| Q1 2026 Earnings Presentation | Earnings | 28 slides | May 27, 2026 |
| Technical Presentation (December 2020) | Technical | 14 slides | Dec 16, 2020 |
| Technical Presentation (December 2020) | Technical | 49 slides | Dec 16, 2020 |
| Investor Presentation (February 2019) | Investor deck | 31 slides | Feb 4, 2019 |
| Investor Presentation (October 2018) | Investor deck | 30 slides | Oct 1, 2018 |
| Investor Presentation (June 2018) | Investor deck | 32 slides | June 2018 |
| Investor Presentation (April 2018) | Investor deck | 31 slides | April 2018 |
| Investor Presentation (March 2018) | Investor deck | 32 slides | March 2018 |
| Investor Presentation (December 2017) | Investor deck | 41 slides | Dec 5, 2017 |
All 37 decks
IPO
Withdrawn on Jul 1, 2011. Filed with the SEC to go public on Sep 24, 2010.
- Underwriters
- JMP Securities, Oppenheimer & Co. · In the order on the cover
Steps
| Step | When |
|---|---|
| Filed publicly | Sep 24, 2010 |
| Filing withdrawn | Jul 1, 2011 |
Filings
| Filing | Filed |
|---|---|
| RW · Request to withdraw a registration | Jul 1, 2011 |
| F-1 · Registration statement | Sep 24, 2010 |
Open IPO · From the cover of the prospectus (F-1) filed Sep 24, 2010
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.18M | 28.9M | 4.80M | 0 | 0 | |||||
| Cost of revenue | 230.0K | 9.26M | 3.69M | 0 | 0 | |||||
| Gross profit | 950.0K | 19.7M | 1.11M | 0 | 0 | |||||
| Research and development | 8.09M | 9.15M | 12.5M | 17.6M | 19.5M | 18.2M | 23.4M | 19.8M | 19.5M | 11.2M |
| Selling, general and administrative | 3.14M | 6.32M | 6.31M | 5.07M | 4.31M | 3.91M | 3.82M | 4.43M | 4.04M | 3.98M |
| Operating income | -10.3M | -20.4M | -49.7M | -29.2M | -24.8M | -22.9M | -28.1M | -25.6M | -25.2M | -16.5M |
| Depreciation and amortization | 523.0K | 4.07M | 1.38M | 654.0K | 703.0K | 934.0K | 940.0K | 545.0K | 481.0K | 482.0K |
| EBITDA | -9.76M | -16.3M | -48.3M | -28.5M | -24.1M | -22.0M | -27.2M | -25.1M | -24.8M | -16.0M |
| Interest expense | 1.25M | 9.07M | 2.14M | 1.79M | 984.0K | 1.47M | 2.28M | 473.0K | 21.0K | 22.0K |
| Income tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||
| Net income | -2.03M | -9.22M | -60.6M | -25.0M | -27.1M | -30.0M | -25.4M | -23.0M | -24.4M | -15.8M |
| Earnings per share, basic | 0.00 | -0.01 | -0.06 | -0.03 | -0.04 | -0.12 | ||||
| Earnings per share, diluted | 0.00 | -0.01 | -0.06 | -0.03 | -0.04 | -0.12 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 3.25M | 10.4M | 4.25M | 10.6M | 13.0M | 16.8M | 5.30M | 3.40M | 5.11M | 2.47M |
| Inventory | 2.15M | 3.15M | 1.95M | 0 | ||||||
| Current assets | 23.7M | 27.1M | 47.2M | 52.0M | 57.4M | 22.9M | 28.2M | 32.0M | 50.4M | 36.1M |
| Property, plant and equipment | 160.0K | 386.0K | 473.0K | 726.0K | 952.0K | 1.34M | 1.82M | 2.23M | 2.50M | 2.60M |
| Total assets | 40.9M | 38.9M | 63.9M | 76.4M | 81.4M | 47.3M | 53.6M | 56.2M | 61.0M | 38.9M |
| Accounts payable | 3.49M | 5.58M | 10.9M | 6.97M | 5.57M | 5.92M | 7.79M | 4.49M | 5.52M | 2.59M |
| Current liabilities | 12.1M | 15.4M | 42.8M | 10.7M | 9.72M | 10.6M | 12.0M | 6.75M | 6.72M | 3.66M |
| Total debt | 4.48M | 4.48M | 3.15M | 1.54M | 2.76M | 5.83M | 8.49M | 8.73M | 250.0K | 343.0K |
| Total liabilities | 17.6M | 25.4M | 50.7M | 25.5M | 13.3M | 25.3M | 20.2M | 14.9M | 8.08M | 3.91M |
| Shareholders' equity | 18.2M | 13.5M | 13.2M | 50.8M | 68.1M | 22.0M | 33.4M | 41.3M | 52.9M | 35.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -8.07M | -43.9M | -22.6M | -26.2M | -23.6M | -23.2M | -22.7M | -24.2M | -20.5M | -14.5M |
| Capital spending | -25.0K | -53.0K | -116.0K | -131.0K | -97.0K | 0 | -67.0K | -173.0K | -338.0K | -52.0K |
| Free cash flow | -8.10M | -43.9M | -22.7M | -26.4M | -23.7M | -23.2M | -22.7M | -24.4M | -20.9M | -14.6M |
| Cash from investing | -8.54M | 29.4M | 1.44M | 4.01M | -38.2M | 16.7M | 5.26M | 9.55M | -15.9M | 9.30M |
| Cash from financing | 8.88M | 20.7M | 15.1M | 20.4M | 57.7M | 17.9M | 19.2M | 13.1M | 38.7M | 2.09M |
| Change in cash | -7.74M | 6.16M | -6.11M | -1.80M | -4.05M | 11.3M | 1.78M | -1.54M | 2.21M | -3.13M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 6-K · Report of a foreign issuer | Nov 18, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 6-K · Report of a foreign issuer | Nov 16, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Oct 23, 2026 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Oct 5, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Oct 2, 2026 | Offer document | SEC |
| F-1 · Registration statement | Sep 25, 2026 | Offer document | SEC |
| 6-K · Report of a foreign issuer | Sep 24, 2026 | Current report | SEC |
| 6-K · Report of a foreign issuer | Sep 10, 2026 | Current report | SEC |
| D | Sep 9, 2026 | Other filings | SEC |
Show 200 filings
This page holds 200 of 620 filings. Open Filings
Cap table
Built by 6ix from BioLineRX Ltd.’s releases
- Common shares
- 2,986,929,790
- Fully diluted
- 2,986,929,790
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 2,986,929,790 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 2,986,929,790 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Barbara-Jean Anne Bormann-Kennedy Other companies: Xeris Biopharma Holdings, Inc. (Director · Since at least Oct 5, 2021); BetterLife Pharma Inc. (President, Director · Feb 5, 2015 – Feb 5, 2015 · Past) | Director · Since at least Mar 18, 2026 |
| Aharon Schwartz Other companies: Protalix BioTherapeutics, Inc. (de) (Director · Since at least Nov 10, 2014) | Director · Since at least Mar 18, 2026 |
| BJ Bormann Other companies: Xeris Biopharma Holdings, Inc. (Independent, Non-executive Board Member · Since at least Nov 5, 2026) | BOARD MEMBER · Since at least Nov 6, 2026 |
| Philip A Serlin Other companies: XWELL, Inc. (Director · Feb 15, 2012 – Mar 13, 2012 · Past) | Chief Executive Officer · Since at least Mar 18, 2026 |
| Raphael Hofstein Other companies: Scopus BioPharma, Inc. (Director · Dec 16, 2020 – Dec 16, 2020 · Past) | Director · Since at least Mar 18, 2026 |
| Avraham Molcho | BOARD MEMBER · Since at least Mar 18, 2026 |
| Bela Neiman | VICE PRESIDENT, ANALYTICAL CHEMISTRY · Since at least Nov 6, 2026 |
| Efrat Halbfinger | VICE PRESIDENT, CHEMISTRY AND FORMULATION · Since at least Nov 6, 2026 |
| Ella Sorani | CHIEF DEVELOPMENT OFFICER · Since at least Nov 6, 2026 |
| Gal Cohen | BOARD MEMBER · Since at least Mar 18, 2026 |
All 18 people
| Person | Seat |
|---|---|
| Irit Gliko-Kabir | VICE PRESIDENT, CLINICAL OPERATIONS · Since at least Nov 6, 2026 |
| Jael Birenberg | VICE PRESIDENT, REGULATORY AFFAIRS, QUALITY ASSURANCE & PHARMACOVIGILANCE · Since at least Nov 6, 2026 |
| Mali Zeevi | CHIEF FINANCIAL OFFICER · Since at least Mar 18, 2026 |
| Philip A. Serlin | CHIEF EXECUTIVE OFFICER · Since at least Sep 10, 2026 |
| Rafael Hofstein | BOARD MEMBER · Since at least Nov 6, 2026 |
| Rami Dar | BOARD MEMBER · Since at least Mar 18, 2026 |
| Sandra Panem | BOARD MEMBER · Since at least Mar 18, 2026 |
| Shaoyu Yan | BOARD MEMBER · Since at least Mar 18, 2026 |
Log in to ask 6ix AI your own questions about BioLineRX Ltd.